Novo Nordisk A/S, a foreign private issuer, has submitted a Form 6-K report to the United States Securities and Exchange Commission (SEC) on April 24, 2024. The report, which is a requirement for foreign companies listed on U.S. stock exchanges, provides updates and information that the company deems significant. The submission of the Form 6-K indicates Novo Nordisk A/S's compliance with the SEC's rules, specifically Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The document was officially signed by an authorized representative of Novo Nordisk A/S on the date of filing. The company's principal executive offices are located at Novo Allé 1, DK-2880, Bagsvaerd, Denmark.

Novo Nordisk A/S, a foreign private issuer, has submitted a Form 6-K report to the United States Securities and Exchange Commission (SEC) on April 24, 2024. The report, which is a requirement for foreign companies listed on U.S. stock exchanges, provides updates and information that the company deems significant. The submission of the Form 6-K indicates Novo Nordisk A/S's compliance with the SEC's rules, specifically Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The document was officially signed by an authorized representative of Novo Nordisk A/S on the date of filing. The company's principal executive offices are located at Novo Allé 1, DK-2880, Bagsvaerd, Denmark.